<style face="normal" font="default" size="100%">897-B A <em>DNAJB1-PRKACA</em> fusion peptide vaccine combined with ipilimumab and nivolumab elicits polyclonal fusion-specific T cell responses in fibrolamellar carcinoma</style>

Drupal-HighWire